A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial.

Trial Profile

A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms ACROSS
  • Sponsors Takeda; Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 17 Oct 2013 Results published in Chest.
    • 18 Aug 2012 Actual end date (May 2012 ) added as reported by ClinicalTrials.gov.
    • 23 May 2012 Chinese Clinical Trial Register reports trial status as recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top